Parkinson’s disease causality and heterogeneity: a proteogenomic view - Kaiser, Sergio; Zhang, Luqing; Mollenhauer, Brit; Jacob, Jaison; Longerich, Simonne; Del-Aguila, Jorge; Marcus, Jacob; Raghavan, Neha; Stone, David; Fagboyegun, Olumide; Galasko, Douglas; Dakna, Mohammed; et al. (medRxiv, 2022)
The pathogenesis and clinical heterogeneity of Parkinson’s disease have been evaluated from molecular, pathophysiological, and clinical perspectives. High-throughput proteomic analysis of CSF has opened new opportunities for scrutinizing this heterogeneity. To date, this is the most comprehensive CSF-based proteomics profiling study in Parkinson’s disease (1103 patients, 4135 proteins). Combining CSF aptamer-based proteomics with genetics we determined protein quantitative trait loci (pQTLs). Analyses of pQTLs together with summary statistics from the largest Parkinson’s disease genome wide association study (GWAS) identified 68 potential causal proteins by Mendelian randomization. The top causal protein, GPNMB was previously reported to be upregulated in the substantia nigra of Parkinson’s disease patients.We also compared the CSF proteomes of patients and controls. The Parkinson’s disease cohort comprised not only LRRK2+ and GBA+ mutation carriers but also idiopathic patients. Proteome differences between GBA+ patients and unaffected GBA+ controls suggest degeneration of dopaminergic neurons, altered dopamine metabolism and increased brain inflammation. The proteins discriminating LRRK2+ patients from unaffected LRRK2+ controls, revealed dysregulated lysosomal degradation, as well as altered alpha-synuclein processing, and neurotransmission. Proteome differences between idiopathic patients and controls suggest increased neuroinflammation, mitochondrial dysfunction / oxidative stress, altered iron metabolism and potential neuroprotection mediated by vasoactive substances.Finally, we used proteomic data to stratify idiopathic patients into “endotypes”. The identified endotypes show differences in cognitive and motor disease progression based on the use of previously reported protein-based risk scores.In summary, we: i) identified causal proteins for Parkinson’s disease, ii) assessed CSF proteome differences in Parkinson’s disease patients of genetic and idiopathic etiology, and. iii) stratified idiopathic patients into robust clinically relevant subtypes. Our findings not only contribute to the identification of new therapeutic targets but also to shaping personalized medicine in CNS neurodegeneration.Competing Interest StatementThe study was supported by the Novartis Institutes for Biomedical Research and Merck. Protein measurements were performed at SomaLogic. A.K., B.B., B.P. F.E., J.J., J.L., L.Z., M. Dovlatyan, M.M., M.R., P.S-F., S.K. and V.S. are or have been employees of Novartis; J.J., S.K., M.M. are also stockholders of Novartis. D.S., J.D-A., J.M., N.R. and S.L. are or have been employees of Merck. All other authors have no conflict of interests to declare.Funding StatementThe study was supported by the Novartis Institutes for Biomedical Research and Merck.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples we have used for the study are available in the PPMI repositoryI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results of the current study are publicly available on the LONI database and all data produced in the present work are contained in the manuscriptAUCArea Under the CurveFDRFalse Discovery RateGWASGenome-wide Association StudyLDLinkage DisequilibriumMAFMajor Allele FrequencyMDSMovement Disorder SocietyMoCAMontreal Cognitive AssessmentngPD-ProSnon-genetic Parkinson’s Disease-associated Proteomic ScorePPMIParkinson Progression Marker InitiativepQTLProteomic Quantitative Trait LocusQCQuality ControlSOMAmerSlow Off-rate Modified AptamerSNPSingle Nucleotide PolymorphismUPDRSUnified Parkinson’s Disease Rating ScaleWGCNAWeighted Gene Co-expression Network Analysis